Pharmacology and Therapeutics - Research Publications

Permanent URI for this collection

http://hdl.handle.net/11343/178

Filters

2014 1
1
Reset filters

Settings
Statistics
Citations
Start date: 2014 × End date: 2019 × Subject: AUTOTAXIN ×

Search Results

Now showing 1 - 1 of 1
  • Item
    Thumbnail Image
    Anti-lysophosphatidic acid antibodies improve traumatic brain injury outcomes
    Crack, PJ ; Zhang, M ; Morganti-Kossmann, MC ; Morris, AJ ; Wojciak, JM ; Fleming, JK ; Karve, I ; Wright, D ; Sashindranath, M ; Goldshmit, Y ; Conquest, A ; Daglas, M ; Johnston, LA ; Medcalf, RL ; Sabbadini, RA ; Pebay, A (BIOMED CENTRAL LTD, 2014-02-27)
    BACKGROUND: Lysophosphatidic acid (LPA) is a bioactive phospholipid with a potentially causative role in neurotrauma. Blocking LPA signaling with the LPA-directed monoclonal antibody B3/Lpathomab is neuroprotective in the mouse spinal cord following injury. FINDINGS: Here we investigated the use of this agent in treatment of secondary brain damage consequent to traumatic brain injury (TBI). LPA was elevated in cerebrospinal fluid (CSF) of patients with TBI compared to controls. LPA levels were also elevated in a mouse controlled cortical impact (CCI) model of TBI and B3 significantly reduced lesion volume by both histological and MRI assessments. Diminished tissue damage coincided with lower brain IL-6 levels and improvement in functional outcomes. CONCLUSIONS: This study presents a novel therapeutic approach for the treatment of TBI by blocking extracellular LPA signaling to minimize secondary brain damage and neurological dysfunction.